Corinne Epperly
Director/Board Member at IN8BIO, INC.
Net worth: 96 721 $ as of 2024-03-30
Profile
Corinne D.
Epperly is a professional with experience in various firms.
She has worked as a Director at IN8bio, Inc. since 2023.
Previously, she worked as an Independent Director at AVEO Pharmaceuticals, Inc. from 2021 to 2023, a Research Analyst at Goldman Sachs International in 2010, the Chief Operating Officer at Vascular Biogenics Ltd.
from 2017 to 2018, the Senior Vice President-Strategy & Operations at Iovance Biotherapeutics, Inc. from 2019 to 2020, and the Chief Operating Officer at Cargo Therapeutics, Inc. from 2021 to 2023.
Dr. Epperly received her undergraduate degree from the University of Virginia and her graduate and doctorate degrees from The University of North Carolina at Charlotte.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IN8BIO, INC.
0.19% | 2024-02-06 | 81,967 ( 0.19% ) | 96 721 $ | 2024-03-30 |
Corinne Epperly active positions
| Companies | Position | Start |
|---|---|---|
| IN8BIO, INC. | Director/Board Member | 2023-12-06 |
Former positions of Corinne Epperly
| Companies | Position | End |
|---|---|---|
| CARGO THERAPEUTICS, INC. | Chief Operating Officer | 2023-11-30 |
| AVEO PHARMACEUTICALS, INC. | Director/Board Member | 2023-01-18 |
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 2019-12-31 |
| NOTABLE LABS, LTD. | Chief Operating Officer | 2017-12-31 |
Goldman Sachs International
 Goldman Sachs International Financial ConglomeratesFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Analyst-Equity | 2010-09-30 |
Training of Corinne Epperly
| University of Virginia | Undergraduate Degree |
| The University of North Carolina at Charlotte | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| CARGO THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Goldman Sachs International
Goldman Sachs International Financial ConglomeratesFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Finance |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
- Stock Market
- Insiders
- Corinne Epperly
